CN112654357B - 用于治疗非酒精性脂肪性肝炎的组合物和方法 - Google Patents

用于治疗非酒精性脂肪性肝炎的组合物和方法 Download PDF

Info

Publication number
CN112654357B
CN112654357B CN201980058395.1A CN201980058395A CN112654357B CN 112654357 B CN112654357 B CN 112654357B CN 201980058395 A CN201980058395 A CN 201980058395A CN 112654357 B CN112654357 B CN 112654357B
Authority
CN
China
Prior art keywords
subject
nash
pharmaceutically acceptable
mice
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980058395.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN112654357A (zh
Inventor
M·威廉姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arjenon Pharmaceutical Co ltd
Original Assignee
Arjenon Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arjenon Pharmaceutical Co ltd filed Critical Arjenon Pharmaceutical Co ltd
Publication of CN112654357A publication Critical patent/CN112654357A/zh
Application granted granted Critical
Publication of CN112654357B publication Critical patent/CN112654357B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN201980058395.1A 2018-07-06 2019-07-03 用于治疗非酒精性脂肪性肝炎的组合物和方法 Active CN112654357B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694848P 2018-07-06 2018-07-06
US62/694,848 2018-07-06
US201962809351P 2019-02-22 2019-02-22
US62/809,351 2019-02-22
PCT/CA2019/050915 WO2020006631A1 (en) 2018-07-06 2019-07-03 Compositions and methods for treating non-alcoholic steatohepatitis

Publications (2)

Publication Number Publication Date
CN112654357A CN112654357A (zh) 2021-04-13
CN112654357B true CN112654357B (zh) 2024-02-13

Family

ID=69060680

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980058395.1A Active CN112654357B (zh) 2018-07-06 2019-07-03 用于治疗非酒精性脂肪性肝炎的组合物和方法

Country Status (6)

Country Link
US (1) US11744808B2 (enExample)
EP (2) EP4541352A3 (enExample)
JP (1) JP7399949B2 (enExample)
CN (1) CN112654357B (enExample)
CA (1) CA3105850A1 (enExample)
WO (1) WO2020006631A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020191503A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders
WO2020191501A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders
EP4196584A2 (en) * 2020-08-13 2023-06-21 Amgen Inc. Rnai constructs and methods for inhibiting marc1 expression
IT202100014177A1 (it) * 2021-05-31 2022-12-01 Sunnutrapharma S R L Utilizzo della istradefillina per ridurre la fibrosi d’organo
CN115778957B (zh) * 2022-11-04 2024-06-21 天津中医药大学 千金藤素及包含其的组合物用于预防或治疗酒精性肝病的应用
CN118512532A (zh) * 2024-06-17 2024-08-20 重庆医科大学 一种含千金藤素的中成药组合物及其在非酒精性脂肪肝上的应用
CN120346213B (zh) * 2025-05-13 2025-10-24 中国医科大学 CD39抑制剂或A2a受体抑制剂在制备治疗非酒精性脂肪肝炎产品中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002114672A (ja) * 2000-10-10 2002-04-16 Yukihiko Matsuda Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤
WO2009007679A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
CN104271574A (zh) * 2012-02-20 2015-01-07 武田药品工业株式会社 杂环化合物
WO2017100500A1 (en) * 2015-12-11 2017-06-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vesicle containing metallic nanoparticle and method for production thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2175229C2 (ru) * 1999-12-22 2001-10-27 Научно-исследовательский институт фармакологии РАМН Анксиолитическое средство
RU2261709C2 (ru) * 2003-08-15 2005-10-10 Государственное учреждение Научно-исследовательский институт фармакологии Российской Академии медицинских наук Психостимулирующее средство
US20100056552A1 (en) * 2007-03-30 2010-03-04 Johan Raud Combination for use in the treatment of inflammatory disorders
WO2012157290A1 (ja) 2011-05-19 2012-11-22 富士化学工業株式会社 非アルコール性脂肪性肝炎の予防改善剤
RU2547141C1 (ru) * 2014-02-28 2015-04-10 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) Способ получения n-(4-бромфенил)-n-(2-адамантил)амина (бромантана)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002114672A (ja) * 2000-10-10 2002-04-16 Yukihiko Matsuda Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤
WO2009007679A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
CN104271574A (zh) * 2012-02-20 2015-01-07 武田药品工业株式会社 杂环化合物
WO2017100500A1 (en) * 2015-12-11 2017-06-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vesicle containing metallic nanoparticle and method for production thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IIKURA 等."Effect of suplatst tosilate, a Th2 cytokine inhibitor,on murine food allergy model on the small intestine and liver damages".《 JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY》.2003,第111卷 *
支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗及教育和管理方案);中华医学会呼吸病学分会哮喘学组;中华内科杂志(11);全文 *

Also Published As

Publication number Publication date
EP3817749A1 (en) 2021-05-12
US11744808B2 (en) 2023-09-05
EP3817749A4 (en) 2022-05-04
EP4541352A3 (en) 2025-07-16
US20210290566A1 (en) 2021-09-23
EP4541352A2 (en) 2025-04-23
WO2020006631A1 (en) 2020-01-09
CA3105850A1 (en) 2020-01-09
JP2021535175A (ja) 2021-12-16
JP7399949B2 (ja) 2023-12-18
CN112654357A (zh) 2021-04-13

Similar Documents

Publication Publication Date Title
JP7399949B2 (ja) 非アルコール性脂肪性肝炎治療のための組成物及び方法
US12318375B2 (en) Method of treatment with tradipitant
US12280026B2 (en) Use of repirinast in the prophylaxis or treatment of renal fibrosis or kidney disease
JP2011502997A5 (enExample)
CN107635566A (zh) 治疗hbv感染的组合物和方法
JP2020500864A5 (enExample)
JP6509729B2 (ja) 慢性腎臓病の進行抑制又は改善剤
JP2022514152A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
CN102892760B (zh) 非醇性脂肪性肝炎的预防和/或治疗剂
Peharda et al. Pruritus an important symptom of
WO2022253034A1 (zh) 吡咯并嘧啶类化合物的用途
Mayer et al. S1095 the pharmacokinetics of TAK-390mr 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and lansoprazole 60 mg: a retrospective analysis
US11712427B2 (en) Method for increasing serum adiponectin for treatment and reduction of the risk of cardiovascular, vascular, and related diseases
Yuan et al. S1093 Dose-Effect of S-Tenatoprazole-Na in Healthy Volunteers: A Meta-Analysis of Individual Subject Data from Four Pharmacodynamic Studies
WO2021262749A1 (en) Compositions and methods for preventing and/or treating viral infection
RU2537223C2 (ru) Способ оптимизации лечения иматинибом пролиферативных заболеваний, опосредованных рецептором тирозинкиназы kit
CN104053441B (zh) 用于预防或治疗高脂血症的药物组合物
JP6465592B2 (ja) 涙液分泌促進組成物
CN105273031B (zh) 新颖的三萜化合物及其用途
WO2020191503A1 (en) Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders
JP2013537232A5 (enExample)
CN101646439A (zh) 减少超重或肥胖的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant